

Professor Claire Harrison's publications

Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. Harrison CN, Talpaz M, Mead AJ. *Leuk Lymphoma*. 2016 Oct;57(10):2259-67.

Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. Beauverd Y, Alimam S, McLornan DP, Radia DH, Harrison CN. *Br J Haematol*. 2016 Jun 13.

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Harrison CN, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoop L, Cervantes F, Jones MM, Sun K, McQuitty M, Stalbovskaya V, Gopalakrishna P, Barbui T. *Leukemia*. 2016 Aug;30(8):1701-7.

Safety considerations when treating myelofibrosis. O'Sullivan JM, McLornan DP, Harrison CN. *Expert Opin Drug Saf*. 2016 Jun 1:1-8. [Epub ahead of print]

Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms. Curto-García N, Harrison CN, McLornan DP, Radia DH. *Br J Haematol*. 2016 May 2..

Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Verstovsek S, Vannucchi AM, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Kirito K, Besses C, Hino M, Moiraghi B, Miller CB, Cazzola M, Rosti V, Blau I, Mesa R, Jones MM, Zhen H, Li J, Francillard N, Habr D, Kiladjian JJ. *Haematologica*. 2016 Jul;101(7):821-9.

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group. Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA. *Cancer*. 2016 Jun 15;122(12):1888-96. doi: 10.1002/cncr.30013. Epub 2016 Apr 12.

JAK inhibitors truly changing the therapeutic paradigm in myelofibrosis. Harrison CN. *J Med Econ*. 2016;19(4):443-4.

How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. Reiter A, Harrison C. *Curr Hematol Malig Rep*. 2016 Feb 19. [Epub ahead of print]

JAK inhibitors truly changing the therapeutic paradigm in myelofibrosis. Harrison CN. *Med Econ*. 2016 Feb 18:1-2. [Epub ahead of print] No abstract available.

Beneficial effects of JAK inhibitor therapy in Systemic Mastocytosis. Dowse R, Ibrahim M, McLornan DP, Moonim MT, Harrison CN, Radia DH. *Br J Haematol*. 2016 Feb 5. doi: 10.1111/bjh.13951. [Epub ahead of print]

Ruxolitinib: evolution or revolution in treatment of patients with polycythemia vera?
Beauverd Y, McLornan DP, Radia DH, Harrison CN. *Future Oncol*. 2016 Mar;12(6):739-49. doi: 10.2217/fon-2015-0023.

Pegylated interferon alpha-2a for essential thrombocythaemia during pregnancy, outcome and safety: a case series. Beauverd Y, Radia D, Cargo C, Knapper S, Drummond M, Pillai A, Harrison C, Robinson S. *Haematologica*. 2016 Jan 27. pii: haematol.2015.139691.

Closing the gap: genetic landscape of MPN.
Harrison CN, Vannucchi AM. *Blood*. 2016 Jan 21;127(3):276-8.

Comprehensively understanding fatigue in patients with myeloproliferative neoplasms. Scherber RM, Kosiorek HE, Senyak Z, Dueck AC, Clark MM, Boxer MA, Geyer HL, McCallister A, Cotter M, Van Husen B, Harrison CN, Mesa RA. *Cancer*. 2015 Dec 15. doi: 10.1002/cncr.29753. [Epub ahead of print]

STAT1 activation in association with JAK2 exon 12 mutations.
Godfrey AL, Chen E, Massie CE, Silber Y, Pagano F, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, Boiron JM, Döhner K, Vannucchi AM, Besses C, Green AR. *Haematologica*. 2015 Dec 3. pii: haematol.2015.128546. [Epub ahead of print]

Myeloproliferative neoplasms and personalized medicine: the perfect match?
Kiladjian JJ, Harrison C. *Haematologica*. 2015 Dec;100(12):1493-4

Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Standard Therapy.
Mesa R, Verstovsek S, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Zhen H, Jones MM, Parasuraman S, Li J, Côté I, Habr D, Vannucchi AM. *Eur J Haematol*. 2015 Nov 26. doi: 10.1111/ejh.12707. [Epub ahead of print]

Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Fuentes AK, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Maldonado N, Barosi G, Ferrari ML, Gale RP, Birgegard G, Xu Z, Zhang Y, Sun X, Xu J, Zhang P, Te Boekhorst PA, Commandeur S, Schouten H, Pahl HL, Griesshammer M, Stegelmann F, Lehmann T, Senyak Z, Vannucchi AM, Passamonti F, Samuelsson J, Mesa RA. *J Clin Oncol*. 2015 Nov 23. pii: JCO629337. [Epub ahead of print]

Management of polycythaemia vera: a critical review of current data.
McMullin MF, Wilkins BS, Harrison CN. *Br J Haematol*. 2015 Oct 22. doi: 10.1111/bjh.13812.

How we diagnose and treat essential thrombocythaemia.
Alimam S, Wilkins BS, Harrison CN. *Br J Haematol*. 2015 Nov;171(3):306-21.

Pacritinib: a new agent for the management of myelofibrosis?
Beauverd Y, McLornan DP, Harrison CN. *Expert Opin Pharmacother*. 2015;16(15):2381-90

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.

Vannucchi AM, Kantarjian HM, Kiladjan JJ, Gotlib J, Cervantes F, Mesa RA, Sarlis NJ, Peng W, Sandor V, Gopalakrishna P, Hmissi A, Stalbovska V, Gupta V, Harrison C, Verstovsek S; COMFORT Investigators.

Haematologica. 2015 Sep;100(9):1139-45.

JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells.

Keohane C, Kordasti S, Seidl T, Perez Abellan P, Thomas NS, Harrison CN, McLornan DP, Mufti GJ. Br J Haematol. 2015 Oct;171(1):60-73.

The effects of JAK inhibitor therapy upon novel markers of thrombosis In myeloproliferative neoplasms.

Keohane C, McLornan DP, Sanchez K, Connor C, Radia D, Harrison CN.

Haematologica. 2015 Sep;100(9):e348-50.

Pacritinib: a new agent for the management of myelofibrosis?

Beauverd Y, McLornan DP, Harrison CN. Expert Opin Pharmacother. 2015 Oct;16(15):2381-90.

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis.

McMullin MF, Harrison CN, Niederwieser D, Demuynck H, Jäkel N, Gopalakrishna P, McQuitty M, Stalbovska V, Recher C, Theunissen K, Gisslinger H, Kiladjan JJ, Al-Ali HK. Exp Hematol Oncol. 2015 Sep 15;4:26.

The use of JAK inhibitors for low-risk myelofibrosis.

Alimam S, McLornan D, Harrison C. Expert Rev Hematol. 2015 Oct;8(5):551-3.

How We Treat Myeloproliferative Neoplasms.

Harrison CN, McLornan DP, Francis YA, Woodley C, Provis L, Radia DH. Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S19-26.

Immunological Consequences of JAK Inhibition: Friend or Foe?

McLornan DP, Khan AA, Harrison CN. Curr Hematol Malig Rep. 2015 Aug 21.

The use of JAK inhibitors for low-risk myelofibrosis.

Alimam S, McLornan D, Harrison C. Expert Rev Hematol. 2015 Aug 6:1-3.

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A

Randomized Clinical Trial. Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, Masszi T, Mishchenko E, Jourdan E, Vannucchi AM, Drummond MW, Jurgutis M, Kuliczowski K, Gheorghita E, Passamonti F, Neumann F, Patki A, Gao G, Tefferi A. JAMA Oncol. 2015 Aug 1;1(5):643-51.

Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase? Khan AA,

Harrison CN, McLornan DP. Br J Haematol. 2015 Aug;170(3):323-35.

Novel therapies for myelofibrosis. Stein BL, Cervantes F, Giles F, Harrison CN, Verstovsek S. Leuk Lymphoma. 2015 May 18:1-11.

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Tapper W, Jones AV, Kralovics R, Harutyunyan AS, Zoi K, Leung W, Godfrey AL, Guglielmelli P, Callaway A, Ward D, Aranaz P, White HE, Waghorn K, Lin F, Chase A, Baxter EJ, Maclean C, Nangalia J, Chen E, Evans P, Short M, Jack A, Wallis L, Oscier D, Duncombe AS, Schuh A, Mead AJ, Griffiths M, Ewing J, Gale RE, Schnittger S, Haferlach T, Stegelmann F, Döhner K, Grallert H, Strauch K, Tanaka T, Bandinelli S, Giannopoulos A, Pieri L, Mannarelli C, Gisslinger H, Barosi G, Cazzola M, Reiter A, Harrison C, Campbell P, Green AR, Vannucchi A, Cross NC. *Nat Commun*. 2015 Apr 7;6:6691.

JAK inhibitors and myelofibrosis, Einstein and ruxolitinib. Harrison C. *Haematologica*. 2015 Apr;100(4):409-11

Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Dawson MK, Harrison C. *Br J Haematol*. 2015 Jul;170(1):29-39.

Essential thrombocythaemia. Double G, Harrison C. *Hematology*. 2015 Mar;20(2):119-20

Haemorrhagic thrombocytosis revisited? Lofaro T, Harrison CN. *Eur J Haematol*. 2015 Jan;94(1):1.

Management of MPN beyond JAK2. Harrison CN, Garcia NC. *Hematology Am Soc Hematol Educ Program*. 2014 Dec 5;2014(1):348-54.

Pulmonary arterial hypertension exacerbated by ruxolitinib. Low AT, Howard L, Harrison C, Tulloh RM. *Haematologica*. 2015 Jun;100(6):e244-5.

Effect of mutation order on myeloproliferative neoplasms. Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitropoulou D, Guglielmelli P, Bellosillo B, Besses C, Döhner K, Harrison CN, Vassiliou GS, Vannucchi A, Campbell PJ, Green AR. *N Engl J Med*. 2015 Feb 12;372(7):601-12.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera. Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, Harrison CN, Pane F, Zachee P, Mesa R, He S, Jones MM, Garrett W, Li J, Pirron U, Habr D, Verstovsek S. *N Engl J Med*. 2015 Jan 29;372(5):426-35.

Update in the myeloproliferative neoplasms. Harrison CN, McMullin MF. *Clin Med*. 2014 Dec;14 Suppl 6:s66-70.

How many JAK inhibitors in myelofibrosis? Ferreira BV, Harrison C. *Best Pract Res Clin Haematol*. 2014 Jun;27(2):187-95.

Combination therapy with ruxolitinib plus 5-azacytidine or continuous infusion of low dose cytarabine is feasible in patients with blast-phase myeloproliferative neoplasms. Mwirigi A, Galli S, Keohane C, Raj K, Radia DH, Harrison CN, McLornan DP. *Br J Haematol*. 2014 Dec;167(5):714-6

Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe AS, Green AR, Mikhaeel G, Gilleece MH, Knapper S, Mead AJ, Mesa RA, Sekhar M, Harrison CN. *Br J Haematol*. 2014 Nov;167(3):418-20.

Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. Harrison CN, Butt N, Campbell P, Conneally E, Drummond M, Green AR, Murrin R, Radia DH, Mead A, Reilly JT, Cross NC, McMullin MF. *Br J Haematol*. 2014 Nov;167(3):421-3.

Safety evaluation of ruxolitinib for treating myelofibrosis. Galli S, McLornan D, Harrison C. *Expert Opin Drug Saf*. 2014 Jul;13(7):967-76.

Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey. Ellis MH, Lavi N, Vannucchi A, Harrison C. *Thromb Res*. 2014 Aug;134(2):251-4.

Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Andersen CL, Bjørn ME, McMullin MF, Harrison C, Samuelsson J, Ejerblad E, Zweegman S, Fernandes S, Bareford D, Knapper S, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Skov V, Thomassen M, Kruse T, Grønbæk K, Hasselbalch HC. *Leuk Res*. 2014 Jul;38(7):816-21.

Increasing therapeutic efficacy in MPN. Harrison CN. *Blood*. 2014 Mar 27;123(13):1982-3. doi: 10.1182/blood-2014

Myelofibrosis. Harrison C, McLornan D. *Hematology*. 2014 Mar;19(2):120-1.

Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, Tenedini E, Pieri L, Paoli C, Mannarelli C, Fjerza R, Rumi E, Stalbovskaya V, Squires M, Cazzola M, Manfredini R, Harrison C, Tagliafico E, Vannucchi AM; COMFORT-II Investigators and the Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. *Blood*. 2014 Apr 3;123(14):2157-60.

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, Caramazza D, Pieri L, Rumi E, Gisslinger H, Knoops L, Kiladjian JJ, Mora B, Hollaender N, Pascutto C, Harrison C, Cazzola M. *Blood*. 2014 Mar 20;123(12):1833-5.

Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners? McLornan D, Harrison C. *J Cell Mol Med*. 2013 Nov;17(11):1410-4

Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study. Gugliotta L, Besses C, Griesshammer M, Harrison C, Kiladjian JJ, Coll R, Smith J, Abhyankar B, Birgegård G. *Haematologica*. 2014 Apr;99(4):679-87.

The diagnosis and management of erythrocytosis. Keohane C, McMullin MF, Harrison C. *BMJ*. 2013 Nov 18;347:f6667

Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Geyer HL, Emanuel RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, Zweegman S, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Döhner K, Harrison CN, Radia D, Muxi P, Besses C, Cervantes F, Johansson PL, Andreasson B, Rambaldi A, Barbui T, Vannucchi AM, Passamonti F, Samuelsson J, Birgegard G, Mesa RA. *Blood*. 2014 Feb 19. [Epub ahead of print]

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O'Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du MQ, Greaves M, Bowen D, Huntly BJ, Harrison CN, Cross NC, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR. *N Engl J Med*. 2013 Dec 19;369(25):2391-405.

Ruxolitinib for myelofibrosis--an update of its clinical effects. Kantarjian HM, Silver RT, Komrokji RS, Mesa RA, Tacke R, Harrison CN. *Clin Lymphoma Myeloma Leuk*. 2013 Dec;13(6):638-45. doi: 10.1016/j.clml.2013.09.006. Epub 2013 Oct 2.

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, McQuitty M, Hunter DS, Levy RS, Passamonti F, Barbui T, Barosi G, Harrison CN, Knoop L, Gisslinger H; COMFORT-II investigators. *Blood*. 2013 Dec 12;122(25):4047-53.

Molecular classification of myeloproliferative neoplasms-pros and cons. Qureshi M, Harrison C. *Curr Hematol Malig Rep*. 2013 Dec;8(4):342-50.

Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Wilkins BS, Radia D, Woodley C, Farhi SE, Keohane C, Harrison CN. *Haematologica*. 2013 Dec;98(12):1872-6.

Treatment and management of myelofibrosis in the era of JAK inhibitors. Keohane C, Radia DH, Harrison CN. *Biologics*. 2013;7:189-98. doi: 10.2147/BTT.S34942. Epub 2013 Aug 20. Erratum in: *Biologics*. 2013;7:231.

Anemia management: development of a rapid access anemia and intravenous iron service. Radia D, Momoh I, Dillon R, Francis Y, Cameron L, Fagg TL, Overland H, Robinson S, Harrison CN. *Risk Manag Healthc Policy*. 2013 Aug 6;6:13-22

Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib JR, Gisslinger H, Levy RS, Siulnik A, Gupta V, Khan M, Dipersio JF, McQuitty M, Catalano JV, Hunter DS, Knoop L, Deininger M, Cervantes F, Miller C, Vannucchi AM, Silver RT, Barbui T, Talpaz M, Barosi G, Winton EF, Mendeson E, Harvey JH, Arcasoy MO, Hexner E, Lyons RM, Paquette R, Raza A, Sun W, Sandor V, Kantarjian HM, Harrison C. *Haematologica*. 2013 Aug 2.

Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Jovanovic JV, Ivey A, Vannucchi AM, Lippert E, Oppliger Leibundgut E, Cassinat B, Pallisgaard N, Maroc N, Hermouet S, Nickless G, Guglielmelli P, van der Reijden BA, Jansen JH, Alpermann T, Schnittger S, Bench A, Tobal K, Wilkins B, Cuthill K, McLornan D, Yeoman K, Akiki S, Bryon J, Jeffries S, Jones A, Percy MJ, Schwemmers S, Gruender A, Kelley TW, Reading S, Pancrazzi A, McMullin MF, Pahl HL, Cross NC, Harrison CN, Prchal JT, Chomienne C, Kiladjian JJ, Barbui T, Grimwade D. *Leukemia*. 2013 Jul 17. doi: 10.1038/leu.2013.219.

A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Andersen CL, McMullin MF, Ejerblad E, Zweegman S, Harrison C, Fernandes S, Bareford D, Knapper S, Samuelsson J, Löfvenberg E, Linder O, Andreasson B, Ahlstrand E, Jensen MK, Bjerrum OW, Vestergaard H, Larsen H, Klausen TW, Mourits-Andersen T, Hasselbalch HC. *Br J Haematol*. 2013 Aug;162(4):498-508

The Role of JAK1/2 Inhibitors in the Treatment of Chronic Myeloproliferative Neoplasms. Keohane C, Mesa R, Harrison C. *Am Soc Clin Oncol Educ Book*. 2013;2013:301-5

Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. Harrison CN, Mesa RA, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, Squier M, Sirulnik A, Mendelson E, Zhou X, Copley-Merriman C, Hunter DS, Levy RS, Cervantes F, Passamonti F, Barbui T, Barosi G, Vannucchi AM. *Br J Haematol*. 2013 Jul;162(2):229-39

Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Harrison C, Vannucchi AM. *Ther Adv Hematol*. 2012 Dec;3(6):341-54.

Treatment target in polycythemia vera. McMullin MF, Harrison CN, Kiladjian JJ. *N Engl J Med*. 2013 Apr 18;368(16):1554-5.

Revised response criteria for polycythemia vera and essential thrombocythemia: a ELN and IWG-MRT consensus project. Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian JJ, Lengfelder E, McMullin MF, Passamonti F, Vannucchi AM, Besses C, Gisslinger H, Samuelsson J, Verstovsek S, Hoffman R, Pardanani A, Cervantes F, Tefferi A, Barbui T. *Blood*. 2013 Jun 6;121(23):4778-81

Polycythemia vera: can we do better? Shariff F, Harrison C. *Expert Opin Pharmacother*. 2013 Apr;14(6):687-9.

Diagnostic pathway for the investigation of thrombocytosis. Harrison CN, Butt N, Campbell P, Conneally E, Drummond M, Green AR, Murrin R, Radia DH, Reilly JT, McMullin MF. *Br J Haematol*. 2013 Mar 11.

JAK inhibitors: beyond spleen and symptoms? Cervantes F, Mesa R, Harrison C. *Haematologica*. 2013 Feb;98(2):160-2

Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. Besses C, Kiladjian JJ, Griesshammer M, Gugliotta L, Harrison C, Coll R, Smith J, Abhyankar B, Birgegård G. *Leuk Res*. 2013 Feb;37(2):162-8.

Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study. Kiladjian JJ, Besses C, Griesshammer M, Gugliotta L, Harrison C, Coll R, Smith J, Birgegård G. Clin Drug Investig. 2013 Jan;33(1):55-63.

Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. J Clin Oncol. 2012 Nov 20;30(33):4098-103.

Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. Bench AJ, White HE, Foroni L, Godfrey AL, Gerrard G, Akiki S, Awan A, Carter I, Goday-Fernandez A, Langabeer SE, Clench T, Clark J, Evans PA, Grimwade D, Schuh A, McMullin MF, Green AR, Harrison CN, Cross NC. Br J Haematol. 2013 Jan;160(1):25-34.

Guideline for the diagnosis and management of myelofibrosis. Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, Green AR, Michael NG, Gilleece MH, Hall GW, Knapper S, Mead A, Mesa RA, Sekhar M, Wilkins B, Harrison CN; Writing group: British Committee for Standards in Haematology. Br J Haematol. 2012 158(4):453-71

Erythropoietin provides a useful strategy for treating preoperative anemia in planned elective orthopedic surgery: an analysis of benefit in routine practice. Qureshi M, Momoh I, Bankes M, Earnshaw P, Radia D, Harrison C. Transfusion. 2012 Sep;52(9):2063-4.

Management of myelofibrosis: a survey of current practice in the United Kingdom. Qureshi MR, MacLean C, McMullin MF, Harrison C. J Clin Pathol. 2012;65(12):1124-7.

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subclone. Godfrey AL, Chen E, Pagano F, Ortmann CA, Silber Y, Bellosillo B, Guglielmelli P, Harrison CN, Reilly JT, Stegelmann F, Bijou F, Lippert E, McMullin MF, Boiron JM, Döhner K, Vannucchi AM, Besses C, Campbell PJ, Green AR. Blood. 2012 Sep 27;120(13):2704-7.

Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Campbell PJ, MacLean C, Beer PA, Buck G, Wheatley K, Kiladjian JJ, Forsyth C, Harrison CN, Green AR. Blood. 2012 Aug 16;120(7):1409-11. doi: 10.1182/blood-2012-04-424911.

Janus kinase Inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure? Harrison C, Verstovsek S, McMullin MF, Mesa R. Br J Haematol. 2012 May;157(4):426-37.

Allogeneic stem cell transplantation for myelofibrosis in 2012. McLornan DP, Mead AJ, Jackson G, Harrison CN. Br J Haematol. 2012 May;157(4):413-25.

Positive JAK2-V617F leading to diagnosis of Gaucher's disease. Appiah-Cubi S, Wilkins BS, Harrison C. J Clin Pathol. 2012 Mar 29.

Experience with pegylated Interferon alpha-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients. Gowin K, Thapaliya P, Samuelsson J, Harrison C, Radia D, Andreasson B, Mascarenhas J, Rambaldi A, Barbui T, Rea C, Camoriano J, Gentry A, Kiladjian JJ, O'Connell C, Mesa R. *Haematologica*. 2012 Mar 14. [Epub ahead of print]

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, McQuitty M, Hunter DS, Levy R, Knoops L, Cervantes F, Vannucchi AM, Barbui T, Barosi G. *N Engl J Med*. 2012 Mar 1;366(9):787-98.

Two new mutations in the HIF2A gene associated with erythrocytosis. Percy MJ, Chung YJ, Harrison C, Mercieca J, Hoffbrand AV, Dinardo CL, Santos PC, Fonseca GH, Gualandro SF, Pereira AC, Lappin TR, McMullin MF, Lee FS. *Am J Hematol*. 2012 Apr;87(4):439-42.

RBC-transfusion guidelines update. Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. *Leuk Res*. 2012 May;36(5):659-60.

Emerging treatments for essential thrombocythemia. Okoli S, Harrison C. *J Blood Med*. 2011;2:151-9. Epub 2011 Dec 2.

Management of myelofibrosis - where next? Qureshi M, Harrison C. *Expert Opin Pharmacother*. 2011 Jul;12(10):1453-5.

The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA. *Blood*. 2011 Jul 14;118(2):401-8..

Myeloproliferative disorders in pregnancy. Harrison CN, Robinson SE. *Hematol Oncol Clin North Am*. 2011 Apr;25(2):261-75, vii.

Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera. Harrison C. *Hematology Am Soc Hematol Educ Program*. 2010;2010:129-34. Review.

Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet. *J Clin Oncol*. 2011 Feb 20;29(6):761-70.

Aspirin in low-risk essential thrombocythemia, not so simple after all? Harrison C, Barbui T. *Leuk Res*. 2011 Mar;35(3):286-9.

What are RBC-transfusion-dependence and -independence? Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. *Leuk Res*. 2011 Jan;35(1):8-11.

New versus old blood - the debate continues. Laurie J, Wyncoll D, Harrison C. *Crit Care*. 2010;14(2):130.

Guideline for investigation and management of adults and children presenting with a thrombocytosis. Harrison CN, Bareford D, Butt N, Campbell P, Conneally E, Drummond M, Erber W, Everington T, Green AR, Hall GW, Hunt BJ, Ludlam CA, Murrin R, Nelson-Piercy C, Radia DH, Reilly JT, Van der Walt J, Wilkins B, McMullin MF; British Committee for Standards in Haematology. *Br J Haematol*. 2010 May;149(3):352-75.

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms. Jones AV, Campbell PJ, Beer PA, Schnittger S, Vannucchi AM, Zoi K, Percy MJ, McMullin MF, Scott LM, Tapper W, Silver RT, Oscier D, Harrison CN, Grallert H, Kisialiou A, Strike P, Chase AJ, Green AR, Cross NC. *Blood*. 2010 Jun 3;115(22):4517-23.

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Beer PA, Delhommeau F, LeCouédic JP, Dawson MA, Chen E, Bareford D, Kusec R, McMullin MF, Harrison CN, Vannucchi AM, Vainchenker W, Green AR. *Blood*. 2010 Apr 8;115(14):2891-900.

A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T. *Br J Haematol*. 2010 Mar;148(6):961-3.

A new polycythaemia vera-associated SOCS3 SH2 mutant (SOCS3F136L) cannot regulate erythropoietin responses. Suessmuth Y, Elliott J, Percy MJ, Inami M, Attal H, Harrison CN, Inokuchi K, McMullin MF, Johnston JA. *Br J Haematol*. 2009 Nov;147(4):450-8.

Identification of high oxygen affinity hemoglobin variants in the investigation of patients with erythrocytosis. Percy MJ, Butt NN, Crotty GM, Drummond MW, Harrison C, Jones GL, Turner M, Wallis J, McMullin MF. *Haematologica*. 2009 Sep;94(9):1321-2.

Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. Campbell PJ, Bareford D, Erber WN, Wilkins BS, Wright P, Buck G, Wheatley K, Harrison CN, Green AR. *J Clin Oncol*. 2009 Jun 20;27(18):2991-9.

British Society for Haematology, slide session, annual scientific meeting, Glasgow, 2008. Hutchinson CV, Burthem J, Bisland M, Carey P, Crotty G, Devalia V, Janda B, Gordon W, Harrison CN, Murray J, Shlebak A, Thomas A, Wilkins B, McMullin MF. *Int J Lab Hematol*. 2010 Apr;32(2):174-83.

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Kiladjan JJ, Lengfelder E, McMullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T. *Blood*. 2009 May 14;113(20):4829-33.

Full blood count. Dillon R, Harrison C. *Br J Hosp Med (Lond)*. 2009 Mar;70(3):M38-41.

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, Pardanani AD, Steensma DP, Litzow MR, Rivera CE, Camoriano J, Verstovsek S, Sloan J, Harrison C, Kantarjian H, Tefferi A. *Leuk Res*. 2009 Sep;33(9):1199-203.

Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones. Beer PA, Jones AV, Bench AJ, Goday-Fernandez A, Boyd EM, Vaghela KJ, Erber WN, Odeh B, Wright C, McMullin MF, Cullis J, Huntly BJ, Harrison CN, Cross NC, Green AR. *Br J Haematol*. 2009 Mar;144(6):904-8.

Do we know more about essential thrombocythemia because of JAK2V617F? Harrison C. *Curr Hematol Malig Rep*. 2009 Jan;4(1):25-32. Review.

Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Fourouclas N, Li J, Gilby DC, Campbell PJ, Beer PA, Boyd EM, Goodeve AC, Bareford D, Harrison CN, Reilly JT, Green AR, Bench AJ. *Haematologica*. 2008 Nov;93(11):1635-44.

Low-dose thalidomide in myelofibrosis. Weinkove R, Reilly JT, McMullin MF, Curtin NJ, Radia D, Harrison CN. *Haematologica*. 2008 Jul;93(7):1100-1.

The management and outcome of four pregnancies in women with idiopathic myelofibrosis. Tulpule S, Bewley S, Robinson SE, Radia D, Nelson-Piercy C, Harrison CN. *Br J Haematol*. 2008 Jul;142(3):480-2.

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatley K, Buck G, Harrison CN, Green AR. *Blood*. 2008;112(1):141-9.

Review: challenges in the management of thrombocytosis in young patients. Robinson S, Harrison C. *Clin Adv Hematol Oncol*. 2008 Feb;6(2):137-8, 141. Review.

The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels. Percy MJ, Scott LM, Erber WN, Harrison CN, Reilly JT, Jones FG, Green AR, McMullin MF. *Haematologica*. 2007 Dec;92(12):1607-14.

Improvement of fibrosis in a patient with chronic myeloproliferative disease. Retter A, Radia DH, Harrison CN. *Br J Haematol*. 2007 Nov;139(3):350.

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL, Paul B, Harrison CN, Green AR, Campbell PJ. *Blood*. 2008;111(1):60-70.

Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. McMullin MF, Reilly JT, Campbell P, Bareford D, Green AR, Harrison CN, Conneally E; National Cancer Research Institute, Myeloproliferative Disorder Subgroup, Ryan K; British Committee for Standards in Haematology. *Br J Haematol*. 2007 Sep;138(6):821-2.

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E. *J Obstet Gynaecol*. 2007 Jan;27(1):82-3.

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, Futreal PA, Erber WN, McMullin MF, Harrison CN, Warren AJ, Gilliland DG, Lodish HF, Green AR. *N Engl J Med*. 2007 Feb 1;356(5):459-68.

A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G, Gisslinger H, Griesshammer M, Gugliotta L, Harrison C, Hasselbalch H, Lengfelder E, Reilly JT, Michiels JJ, Barbui T. *Leukemia*. 2007 Feb;21(2):277-80. Epub 2006 Nov 16.

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. Campbell PJ, Baxter EJ, Beer PA, Scott LM, Bench AJ, Huntly BJ, Erber WN, Kusec R, Larsen TS, Giraudier S, Le Bousse-Kerdilès MC, Griesshammer M, Reilly JT, Cheung BY, Harrison CN, Green AR. *Blood*. 2006 Nov 15;108(10):3548-55.

Essential thrombocythemia/polycythemia vera and pregnancy: the need for an observational study in Europe. Griesshammer M, Struve S, Harrison CM. *Semin Thromb Hemost*. 2006 Jun;32(4 Pt 2):422-9. Review.

Essential thrombocythaemia. Harrison CN, Green AR. *Best Pract Res Clin Haematol*. 2006;19(3):439-53. Review.

Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial. Harrison CN. *Semin Thromb Hemost*. 2006 Apr;32(3):283-8. Review.

Anagrelide for control of thrombocytosis due to myeloproliferative disorders. Harrison CN. *Future Oncol*. 2005 Oct;1(5):609-18. Review.

Mechanisms of thrombosis in essential thrombocythaemia. Harrison C. *Haematologica*. 2006 Feb;91(2):145b.

A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Percy MJ, Zhao Q, Flores A, Harrison C, Lappin TR, Maxwell PH, McMullin MF, Lee FS. *Proc Natl Acad Sci U S A*. 2006 Jan 17;103(3):654-9.

The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. *Br J Haematol*. 2006 Jan;132(2):244-5.

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR; United Kingdom Myeloproliferative Disorders Study Group; Medical Research Council Adult Leukaemia Working Party; Australasian Leukaemia and Lymphoma Group. *Lancet*. 2005 Dec 3;366(9501):1945-53.

Platelets and thrombosis in myeloproliferative diseases. Harrison CN. *Hematology Am Soc Hematol Educ Program*. 2005:409-15.

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis. Campbell PJ, Griesshammer M, Döhner K, Döhner H, Kusec R, Hasselbalch HC, Larsen TS, Pallisgaard N, Giraudier S, Le Bousse-Kerdilès MC, Desterke C, Guerton B, Dupriez B, Bordessoule D, Fenaux P, Kiladjian JJ, Viallard JF, Brière J, Harrison CN, Green AR, Reilly JT. *Blood*. 2006 Mar 1;107(5):2098-100.

The management and outcome of 18 pregnancies in women with polycythemia vera. Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN. *Haematologica*. 2005 Nov;90(11):1477-83.

Essential thrombocythemia. Finazzi G, Harrison C. *Semin Hematol*. 2005 Oct;42(4):230-8. Review.

Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, Oscier D, Polkey MI, Reilly JT, Rosenthal E, Ryan K, Pearson TC, Wilkins B; General Haematology Task Force of the British Committee for Standards in Haematology. *Br J Haematol*. 2005 Jul;130(2):174-95. No abstract available.

Essential thrombocythaemia: challenges and evidence-based management. The management and outcome of 18 pregnancies in women with polycythemia vera. Robinson S, Bewley S, Hunt BJ, Radia DH, Harrison CN. *Haematologica*. 2005 Nov;90(11):1477-83. *Br J Haematol*. 2005 Jul;130(2):153-65. Review.

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. *N Engl J Med*. 2005 Jul 7;353(1):33-45.

Managing the erythrocytoses. Sampson R, Harrison C. *Practitioner*. 2005 May;249(1670):358, 360, 362 passim. Review.

Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Harrison C. *Br J Haematol*. 2005 May;129(3):293-306. Review.

Clonality in essential thrombocythaemia. Harrison C. *Lab Hematol*. 2004;10(3):184-7.

Risk factors for thrombosis in essential thrombocythaemia. Cheung B, Harrison CN. *Clin Lab*. 2004;50(3-4):149-52. Review.

Management of pregnancy complicated by anti-Dib. Win N, Madan B, Harrison C, Needs M. *Transfusion*. 2003 Nov;43(11):1642-3.

Essential thrombocythemia. Harrison CN, Green AR. *Hematol Oncol Clin North Am*. 2003 Oct;17(5):1175-90, vii. Review.

The optimal management of polycythaemia vera. McMullin MF, Bareford D, Craig J, Green AR, Harrison C, Oscier DG, Reilly JT; Myeloproliferative Disorders (UK) Study Group. *Br J Haematol*. 2003 Feb;120(3):543-4;

Monoclonal myelopoiesis and subnormal erythropoietin concentration are independent risk factors for thromboembolic complications in essential thrombocythemia. Andréasson B, Harrison C, Lindstedt G, Linch D, Kutti J. *Blood*. 2003 Jan 15;101(2):783.

Current trends in essential thrombocythaemia. Harrison CN. *Br J Haematol*. 2002 Jun;117(4):796-808. Review.

Patients with essential thrombocythaemia have an increased prevalence of antiphospholipid antibodies which may be associated with thrombosis. Harrison CN, Donohoe S, Carr P, Dave M, Mackie I, Machin SJ. *Thromb Haemost*. 2002 May;87(5):802-7.

Hermansky-Pudlak syndrome: infrequent bleeding and first report of Turkish and Pakistani kindreds. Harrison C, Khair K, Baxter B, Russell-Eggitt I, Hann I, Liesner R. *Arch Dis Child*. 2002 Apr;86(4):297-301.

Hydroxyurea-associated platelet count oscillations in polycythemia vera: a report of four new cases and a review. Steensma DP, Harrison CN, Tefferi A. *Leuk Lymphoma*. 2001 Nov-Dec;42(6):1243-53.

Lack of pathogenic mutations in the 5'-untranslated region of the thrombopoietin gene in patients with non-familial essential thrombocythaemia. Allen AJ, Gale RE, Harrison CN, Machin SJ, Linch DC.

Antenatal antibody screening. New HV, Harrison CN, Rodeck CH, de Silva M, Cohen H. *Lancet*. 2001 Apr 21;357(9264):1295.

High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. Williams CD, Harrison CN, Lister TA, Norton AJ, Blystad AK, Coiffier B, Taghipour G, Schmitz N, Goldstone AH; European Bone Marrow Transplant Lymphoma Working Party. *J Clin Oncol*. 2001 Feb 1;19(3):727-35.

Platelet c-mpl expression is dysregulated in patients with essential thrombocythaemia but this is not of diagnostic value. Harrison CN, Gale RE, Pezella F, Mire-Sluis A, Machin SJ, Linch DC. *Br J Haematol*. 1999 Oct;107(1):139-47.

High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML. Harrison CN, Gregory W, Hudson GV, Devereux S, Goldstone AH, Hancock B, Winfield D, MacMillan AK, Hoskin P, Newland AC, Milligan D, Linch DC. *Br J Cancer*. 1999 Oct;81(3):476-83.

A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Harrison CN, Gale RE, Machin SJ, Linch DC. *Blood*. 1999 Jan 15;93(2):417-24.

Quantification of X-chromosome inactivation patterns using RT-PCR of the polymorphic iduronate-2-sulphatase gene and correlation of the results obtained with DNA-based techniques. Harrison CN, Gale RE, Linch DC. *Leukemia*. 1998 Nov;12(11):1834-9.

The activating splice mutation in intron 3 of the thrombopoietin gene is not found in patients with non-familial essential thrombocythaemia. Harrison CN, Gale RE, Wiestner AC, Skoda RC, Linch DC. *Br J Haematol*. 1998 Sep;102(5):1341-3.

Outcome of secondary myeloid malignancy in Hodgkin's disease: the BNLI experience. Harrison CN, Vaughan G, Devereux S, Linch DC. *Eur J Haematol*. 1998 Aug;61(2):109-12.

Reticulated platelets in primary and reactive thrombocytosis. Robinson MS, Harrison C, Mackie IJ, Machin SJ, Harrison P. *Br J Haematol*. 1998 May;101(2):388-9.

Desirability and problems of early diagnosis of essential thrombocythaemia. Harrison CN, Linch DC, Machin SJ. *Lancet*. 1998 Mar 21;351(9106):846-7.

Acquired skewing of X-chromosome inactivation patterns in myeloid cells of the elderly suggests stochastic clonal loss with age. Gale RE, Fielding AK, Harrison CN, Linch DC. *Br J Haematol*. 1997 Sep;98(3):512-9.

Diagnostic utility of bone marrow sampling in HIV positive patients. Brook MG, Ayles H, Harrison C, Rowntree C, Miller RF. *Genitourin Med*. 1997 Apr;73(2):117-21.

Antiphospholipid antibodies and essential thrombocythemia. Harrison CN, Machin SJ. *Am J Med*. 1997 Mar;102(3):317-8.

Delayed effect of desmopressin on circulating neutrophils and monocytes. Harrison P, Cardigan R, Harrison C, Addison I, Chavda N, Chitolie A, Machin SJ. *Br J Haematol*. 1996 Dec;95(3):570-1.

Plasma exchange with solvent/detergent-treated plasma of resistant thrombotic thrombocytopenic purpura. Harrison CN, Lawrie AS, Iqbal A, Hunter A, Machin SJ. *Br J Haematol*. 1996 Sep;94(4):756-8